1 to 9 of 11 results

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients

Resverlogix’s RVX-208 reduces major adverse cardiovascular events in diabetes mellitus patients


Canadian clinical-stage cardiovascular specialist Resverlogix Corp has announced results it believes…

CanadaCardio-vascularDiabetesNephrology and HepatologyPharmaceuticalResearchResverlogixRVX-208

Cytori licenses Asia-Pacific cardiovascular, renal and diabetes markets to Lorem Vascular for up to $531 million


San Diego, USA-based Cytori Therapeutics and China-headquartered Lorem Vascular have entered a partnership…

Asia-PacificBiotechnologyCardio-vascularCytori TherapeuticsDiabetesLicensingLorem VascularMergers & AcquisitionsNephrology and Hepatology

US FDA accepts NDAs for Otsuka's tolvaptan and BTG's Varisolve


Japanese mid-sized drugmaker Otsuka Pharmaceutical (TYO: 4578) says that the US Food and Drug Administration…

BTGCardio-vascularNephrology and HepatologyNorth AmericaOtsukaPharmaceuticalRare diseasesRegulationtolvaptanVarisolve

High potency statins pose significantly higher risk of kidney injury than low potency, say experts


Patients taking high potency statins for high blood pressure are at a 34% higher risk of being hospitalized…

Cardio-vascularNephrology and HepatologyPharmaceuticalResearch

Japan launches for Lotriga and Argamate


Norway's Pronova BioPharma (OSE: PRON.OL), recently the subject of a $845 million takeover bid from Germany's…

ArgamateAstellas PharmaCardio-vascularLotrigaMarkets & MarketingNephrology and HepatologyNorth AmericaPharmaceuticalPronova BioPharmaSanwa KagakuTakeda Pharmaceuticals

Amgen's Sensipar/Mimpara fails to meet endpoint in CV events for dialysis patients


Amgen (Nasdaq: AMGN), the world's largest independent biotech company, announced top-line results on…

AmgenBiotechnologyCardio-vascularMimparaNephrology and HepatologyResearchSensipar

1 to 9 of 11 results

Back to top